Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: Assessment of the sedative and rewarding effects of GHB

Yossef Itzhak, Syed F. Ali

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Because of the sedative/hypnotic and euphoric effects of gamma-hydroxybutyric acid (GHB), the recreational use of the drug has increased significantly. In the current study we investigated the sedative and rewarding effects of GHB in Swiss Webster mice. Although the acute administration of GHB (200 mg/kg) caused marked hypolocomotion, repeated administration of the drug for 6 or 14 days produced tolerance to this effect. In addition, the administration of GHB 300 mg/kg to naive mice caused catalepsy, which dissipated in mice pre-exposed to GHB (200 mg/kg). Consequently, after repeated treatment with GHB, tolerance developed to both the hypolocomotion and cataleptic effects of the drug. The administration of GHB or its precursor gammabutyrolactone for 14 days increased the striatal content of dopamine. The sedative effects of GHB may be due to hypodopaminergic activity from inhibition of dopamine release and a subsequent increase in the intraneuronal dopamine level. The rewarding effect of GHB was assessed in the conditioned place preference paradigm. Mice treated repeatedly with 250 mg/kg for 7 days developed conditioned preference for the GHB-paired compartment of the cage, suggesting that the GHB cue is rewarding. The development of tolerance to the sedative effects of GHB coupled with the rewarding properties of the drug support the abuse potential of GHB. Further studies are necessary to determine the mechanism underlying the development of tolerance to GHB and the rewarding effect of the drug.

Original languageEnglish
Pages (from-to)451-460
Number of pages10
JournalAnnals of the New York Academy of Sciences
Volume965
StatePublished - Jul 15 2002

Fingerprint

Hypnotics and Sedatives
Dopamine
Pharmaceutical Preparations
4-hydroxybutyric acid
Mouse
Catalepsy
Corpus Striatum
Drugs
Street Drugs
Tolerance
Substance-Related Disorders
Cues

Keywords

  • Brain
  • Drug abuse
  • Gamma-hydroxybuturic acid
  • GHB
  • Hypolocomotion
  • Reward

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Repeated administration of gamma-hydroxybutyric acid (GHB) to mice : Assessment of the sedative and rewarding effects of GHB. / Itzhak, Yossef; Ali, Syed F.

In: Annals of the New York Academy of Sciences, Vol. 965, 15.07.2002, p. 451-460.

Research output: Contribution to journalArticle

@article{c34d384df47e484abd29d15dc6bedf78,
title = "Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: Assessment of the sedative and rewarding effects of GHB",
abstract = "Because of the sedative/hypnotic and euphoric effects of gamma-hydroxybutyric acid (GHB), the recreational use of the drug has increased significantly. In the current study we investigated the sedative and rewarding effects of GHB in Swiss Webster mice. Although the acute administration of GHB (200 mg/kg) caused marked hypolocomotion, repeated administration of the drug for 6 or 14 days produced tolerance to this effect. In addition, the administration of GHB 300 mg/kg to naive mice caused catalepsy, which dissipated in mice pre-exposed to GHB (200 mg/kg). Consequently, after repeated treatment with GHB, tolerance developed to both the hypolocomotion and cataleptic effects of the drug. The administration of GHB or its precursor gammabutyrolactone for 14 days increased the striatal content of dopamine. The sedative effects of GHB may be due to hypodopaminergic activity from inhibition of dopamine release and a subsequent increase in the intraneuronal dopamine level. The rewarding effect of GHB was assessed in the conditioned place preference paradigm. Mice treated repeatedly with 250 mg/kg for 7 days developed conditioned preference for the GHB-paired compartment of the cage, suggesting that the GHB cue is rewarding. The development of tolerance to the sedative effects of GHB coupled with the rewarding properties of the drug support the abuse potential of GHB. Further studies are necessary to determine the mechanism underlying the development of tolerance to GHB and the rewarding effect of the drug.",
keywords = "Brain, Drug abuse, Gamma-hydroxybuturic acid, GHB, Hypolocomotion, Reward",
author = "Yossef Itzhak and Ali, {Syed F.}",
year = "2002",
month = "7",
day = "15",
language = "English",
volume = "965",
pages = "451--460",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Repeated administration of gamma-hydroxybutyric acid (GHB) to mice

T2 - Assessment of the sedative and rewarding effects of GHB

AU - Itzhak, Yossef

AU - Ali, Syed F.

PY - 2002/7/15

Y1 - 2002/7/15

N2 - Because of the sedative/hypnotic and euphoric effects of gamma-hydroxybutyric acid (GHB), the recreational use of the drug has increased significantly. In the current study we investigated the sedative and rewarding effects of GHB in Swiss Webster mice. Although the acute administration of GHB (200 mg/kg) caused marked hypolocomotion, repeated administration of the drug for 6 or 14 days produced tolerance to this effect. In addition, the administration of GHB 300 mg/kg to naive mice caused catalepsy, which dissipated in mice pre-exposed to GHB (200 mg/kg). Consequently, after repeated treatment with GHB, tolerance developed to both the hypolocomotion and cataleptic effects of the drug. The administration of GHB or its precursor gammabutyrolactone for 14 days increased the striatal content of dopamine. The sedative effects of GHB may be due to hypodopaminergic activity from inhibition of dopamine release and a subsequent increase in the intraneuronal dopamine level. The rewarding effect of GHB was assessed in the conditioned place preference paradigm. Mice treated repeatedly with 250 mg/kg for 7 days developed conditioned preference for the GHB-paired compartment of the cage, suggesting that the GHB cue is rewarding. The development of tolerance to the sedative effects of GHB coupled with the rewarding properties of the drug support the abuse potential of GHB. Further studies are necessary to determine the mechanism underlying the development of tolerance to GHB and the rewarding effect of the drug.

AB - Because of the sedative/hypnotic and euphoric effects of gamma-hydroxybutyric acid (GHB), the recreational use of the drug has increased significantly. In the current study we investigated the sedative and rewarding effects of GHB in Swiss Webster mice. Although the acute administration of GHB (200 mg/kg) caused marked hypolocomotion, repeated administration of the drug for 6 or 14 days produced tolerance to this effect. In addition, the administration of GHB 300 mg/kg to naive mice caused catalepsy, which dissipated in mice pre-exposed to GHB (200 mg/kg). Consequently, after repeated treatment with GHB, tolerance developed to both the hypolocomotion and cataleptic effects of the drug. The administration of GHB or its precursor gammabutyrolactone for 14 days increased the striatal content of dopamine. The sedative effects of GHB may be due to hypodopaminergic activity from inhibition of dopamine release and a subsequent increase in the intraneuronal dopamine level. The rewarding effect of GHB was assessed in the conditioned place preference paradigm. Mice treated repeatedly with 250 mg/kg for 7 days developed conditioned preference for the GHB-paired compartment of the cage, suggesting that the GHB cue is rewarding. The development of tolerance to the sedative effects of GHB coupled with the rewarding properties of the drug support the abuse potential of GHB. Further studies are necessary to determine the mechanism underlying the development of tolerance to GHB and the rewarding effect of the drug.

KW - Brain

KW - Drug abuse

KW - Gamma-hydroxybuturic acid

KW - GHB

KW - Hypolocomotion

KW - Reward

UR - http://www.scopus.com/inward/record.url?scp=0036288995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036288995&partnerID=8YFLogxK

M3 - Article

C2 - 12105120

AN - SCOPUS:0036288995

VL - 965

SP - 451

EP - 460

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -